Author

Diogo Bastos

Institution: Latin American Cooperative Oncology Group (LACOG)

Observed institutions: Hospital Sírio-Libanês, Latin American Cooperative Oncology Group (LACOG)

ORCID: 0000-0003-2480-353X

Observed ORCID: 0000-0003-2480-353X

OpenAlex ID: A5106852283

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

2023 · A.O. Siefker-Radtke, N. Matsubara, et al. · Annals of Oncology · 102

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study

2026 · Daniel Herchenhorn, Haonne Abboud, et al. · JCO Global Oncology · 2

177lu-psma in Metastatic Castration Resistant Prostate Cancer: Preliminary Analysis of a Brazilian Multicentric Study

2024 · Victor Cabral Costa Ribeiro Heringer, Felipe P.G. Ribeiro, et al. · Hematology Transfusion and Cell Therapy

Neoantigen Load of Nmibc Tumor Samples Predicts Bcg Response Better Than Neoantigen Quality and Tcr Diversity

2020 · Giulia Wada Friguglietti, Ramon Torreglosa do Carmo, et al. · Brazilian Journal of Oncology

Influence of Hla Class I and Tumor Neoantigens in Treatment Response With Bcg (bacillus Calmette-guérin) Immunotherapy in Non-muscle Invasive Bladder Cancer (nmibc)

2019 · Cibele Cibele, Giulia Wada, et al. · Brazilian Journal of Oncology

Works count: 5

Citation count: 104

H-index: 2

I10-index: 1